HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Effort To Unmask Nanotech Users Begs Question: Why Wear Masks?

This article was originally published in The Rose Sheet

Executive Summary

A Consumers Union report being billed as an exposé of sunscreens that are marketed as nanotech-free but actually contain nanoparticles may signal a need not for FDA's intervention but for industry to take the lead in educating consumers on nanotechnology

You may also be interested in...



Consumers Burned By “Nano-Free” Sunscreens? NGO Cries “Scandal”

Friends of the Earth claims that materials supplier Antaria misleads its customers and ultimately consumers by billing its ZinClear-IM sunscreen ingredient as “nano-free” when third-party testing shows it contains “clusters” of nanoparticles. How nanotechnology should be defined, and exactly what materials warrant special attention from a regulatory standpoint, continues to be a matter of debate internationally.

Badger Reformulates Sunscreens To Meet Consumer Demand For Nano-Free

Amid activist group and consumer concerns about the safety of nanoparticles in sunscreens, W.S. Badger Company has reformulated its sunscreen lineup with non-nano zinc oxide while maintaining product efficacy, the firm says.

Badger Reformulates Sunscreens To Meet Consumer Demand For Nano-Free

Amid activist group and consumer concerns about the safety of nanoparticles in sunscreens, W.S. Badger Company has reformulated its sunscreen lineup with non-nano zinc oxide while maintaining product efficacy, the firm says.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015773

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel